Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$816.9M
258M shares
52-week range
$0.95 – $4.18
68% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.38%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $184.5M | $148.4M | $227.5M | $78.4M | $75.5M | $116.3M | $332.3M | $403.1M |
| Cost of revenue | $265.0K | $0 | $2.4M | $14.2M | $27.0M | $43.3M | $68.6M | $129.2M |
| Gross profit | $184.2M | $148.4M | $225.2M | $64.2M | $48.5M | $73.1M | $263.7M | $273.9M |
| Gross margin | 99.9% | 100.0% | 98.9% | 81.9% | 64.3% | 62.8% | 79.4% | 67.9% |
| R&D | $171.5M | $175.6M | $146.9M | $106.0M | $118.9M | $86.1M | $46.2M | $47.9M |
| Operating income | −$204.6M | −$93.1M | −$121.4M | −$226.7M | −$179.5M | −$155.6M | $54.4M | $60.3M |
| EBITDA | −$204.3M | −$88.7M | −$120.3M | −$222.1M | −$176.3M | −$150.1M | $7.6M | $63.9M |
| Net income | −$201.8M | −$97.2M | −$143.6M | −$269.1M | −$233.7M | −$209.2M | −$51.7M | −$22.7M |
| Net margin | -109.4% | -65.5% | -63.1% | -343.0% | -309.6% | -179.9% | -15.6% | -5.6% |
| EPS (diluted) | -7.54 | -4.02 | -6.05 | -11.03 | -4.33 | -2.03 | -0.28 | -0.11 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $388M | $-0.04 | $-0.05–$-0.03 | 2 |
| 2027 | $449M | $0.27 | $0.25–$0.31 | 4 |
| 2028 | $505M | $0.43 | $-0.61–$1.21 | 4 |
| 2029 | $659M | $0.51 | $0.41–$0.58 | 2 |
Forward consensus · source: Financial Modeling Prep
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
www.esperion.comNo one on the platform currently holds ESPR.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,620,100 | $4.4M |
| Execution date | Ratio |
|---|---|
| 2013-06-11 | 1-for-7reverse |
No one on the platform has traded ESPR yet.
| $437M |
| — |
| OFIXOrthofix Medical Inc. | $9.68 | -1.02% | $391M | — |
| OLMAOlema Pharmaceuticals, Inc. | $12.20 | +7.11% | $1.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 2.3× sales vs its 2.1× historical median P/S.
Fair value ≈ $2.82 · price $3.15 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ESPR sell and buy other stocks. Once deal is done, all you are anticipating are addressed before hand. in small cap, once it is done it is done. Learn and move on.
View on StockTwits ↗$ESPR what’s happening to $SLS is what I thought would happen here. Ugh
View on StockTwits ↗@TonyClifton13 @Gregg617 $ESPR I think people are shorting at a higher prices for example $3 rather than $2.
View on StockTwits ↗$ESPR You’re being robbed! Robbed I tell you at $3.16 a share. https://www.ahajournals.org/doi/10.1161/JAHA.125.047897
View on StockTwits ↗$ESPR Well lookie here! A well respected big lipidologist with statin intolerance and 118k followers is now taking BA (and liking the results) because his insurance will now finally cover the drug because of the new guidelines! Someone tell Sheldon we’re NOT settling for $3.16 a share, get me a competing offer or get me a lawyer!
View on StockTwits ↗$ESPR LOL in rich at Omar…Blocks me and still post at me. I’m over the target. I’m loaded you got that right. Omar’s stocks after I see them, seen below….. These are facts. Takes GUTS to tell another man he’s better than you thanks for noticing me OMArz, gotta run, my dog needs to Omar.
View on StockTwits ↗$ESPR latest weekly scripts included a holiday: Nexlizet down 1.9% and Nexletol down 2.5%. The 3 competitors I look at were down 0.3% to 2.8%. Nothing special.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.